A short, 60 seconds read that summarises 4 handpicked articles that are worth reading about:
What are patient-reported outcomes and why are they important?
Continuing the push for innovation: Key learnings following China’s most recent NRDL update
UK: Lumykras first drug to come through ILAP and receive positive recommendation from NICE
Spain: 92% of CAR-T therapy requests approved for leukaemia patients
Webinar: Discussions on the new Voluntary Scheme for Branded Medicines, Pricing, Access and Growth (...
New website provides regular updates on NLF's work, addresses challenges, and showcases collaboratio...
Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.
Remap Consulting have significant experience working with pharmaceutical and biotech companies in helping them navigate global market access.